Literature DB >> 23250919

Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.

Lin Yao1, Surabhi Chandra, Haroldo A Toque, Anil Bhatta, Modesto Rojas, Ruth B Caldwell, R William Caldwell.   

Abstract

AIMS: We determined the role of the Rho kinase (ROCK) isoforms in diabetes-induced vascular endothelial dysfunction and enhancement of arginase activity and expression. METHODS AND
RESULTS: Studies were performed in aortic tissues from haplo-insufficient (H-I) ROCK1 and ROCK2 mice and wild-type (WT) mice rendered diabetic with streptozotocin and in bovine aortic endothelial cells (BAECs) treated with high glucose (HG, 25 mM). Protein expression of both ROCK isoforms was substantially elevated in aortas of WT mice after 8 weeks of diabetes and in BAECs after 48 h in HG. Impairment of endothelium-dependent vasorelaxation of aortas was observed in diabetic WT mice. However, there was no impairment in aortas of diabetic ROCK1 H-I mice and less impairment in aortas of diabetic ROCK2 H-I mice, compared with non-diabetic mice. These vascular effects were associated with the prevention of diabetes-induced decrease in nitric oxide (NO) production and a rise in arginase activity/expression. Acute treatment with the arginase inhibitor, BEC, improved endothelium-dependent vasorelaxation of aortas of both diabetic WT and ROCK2, but not of ROCK1 mice.
CONCLUSION: Partial deletion of either ROCK isoform, but to a greater extent ROCK1, attenuates diabetes-induced vascular endothelial dysfunction by preventing increased arginase activity and expression and reduction in NO production in type 1 diabetes. Limiting ROCK and arginase activity improves vascular function in diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250919      PMCID: PMC3633399          DOI: 10.1093/cvr/cvs371

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  47 in total

1.  Effect of fasudil on macrovascular disorder-induced endothelial dysfunction.

Authors:  Dhvanit I Shah; Manjeet Singh
Journal:  Can J Physiol Pharmacol       Date:  2006 Aug-Sep       Impact factor: 2.273

2.  Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure.

Authors:  Joseph Winaver; Elena Ovcharenko; Irit Rubinstein; Konstantin Gurbanov; Piero Pollesello; Bishara Bishara; Aaron Hoffman; Zaid Abassi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-12-16       Impact factor: 4.733

3.  Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension.

Authors:  Fruzsina K Johnson; Robert A Johnson; Kelly J Peyton; William Durante
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-12-09       Impact factor: 3.619

4.  Role of Rho-kinase in regulation of insulin action and glucose homeostasis.

Authors:  Noboru Furukawa; Pat Ongusaha; Wan Jin Jahng; Kazushi Araki; Cheol Soo Choi; Hyo-Jeong Kim; Yong Hee Lee; Kozo Kaibuchi; Barbara B Kahn; Hiroaki Masuzaki; Jason K Kim; Sam W Lee; Young-Bum Kim
Journal:  Cell Metab       Date:  2005-08       Impact factor: 27.287

5.  Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

6.  Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction.

Authors:  Xiu-Fen Ming; Christine Barandier; Hema Viswambharan; Brenda R Kwak; François Mach; Lucia Mazzolai; Daniel Hayoz; Jean Ruffieux; Sandro Rusconi; Jean-Pierre Montani; Zhihong Yang
Journal:  Circulation       Date:  2004-11-29       Impact factor: 29.690

7.  Involvement of Rho-kinase in experimental vascular endothelial dysfunction.

Authors:  Dhvanit I Shah; Manjeet Singh
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

8.  Rho-kinase as a molecular target for insulin resistance and hypertension.

Authors:  Takeshi Kanda; Shu Wakino; Koichiro Homma; Kyoko Yoshioka; Satoru Tatematsu; Kazuhiro Hasegawa; Ichiro Takamatsu; Naoki Sugano; Koichi Hayashi; Takao Saruta
Journal:  FASEB J       Date:  2005-11-02       Impact factor: 5.191

9.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.

Authors:  D Fulton; J P Gratton; T J McCabe; J Fontana; Y Fujio; K Walsh; T F Franke; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

10.  The Rho kinases I and II regulate different aspects of myosin II activity.

Authors:  Atsuko Yoneda; Hinke A B Multhaupt; John R Couchman
Journal:  J Cell Biol       Date:  2005-07-25       Impact factor: 10.539

View more
  27 in total

1.  Heterogeneous Impact of ROCK2 on Carotid and Cerebrovascular Function.

Authors:  T Michael De Silva; Dale A Kinzenbaw; Mary L Modrick; Lindsey D Reinhardt; Frank M Faraci
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin Polymerization.

Authors:  Tran Thi Hien; Karolina M Turczyńska; Diana Dahan; Mari Ekman; Mario Grossi; Johan Sjögren; Johan Nilsson; Thomas Braun; Thomas Boettger; Eliana Garcia-Vaz; Karin Stenkula; Karl Swärd; Maria F Gomez; Sebastian Albinsson
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

3.  Hyperglycemia-impaired aortic vasorelaxation mediated through arginase elevation: Role of stress kinase pathways.

Authors:  Surabhi Chandra; David J R Fulton; Ruth B Caldwell; R William Caldwell; Haroldo A Toque
Journal:  Eur J Pharmacol       Date:  2018-11-28       Impact factor: 4.432

Review 4.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

5.  Tissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus.

Authors:  J Pernow; A Kiss; Y Tratsiakovich; B Climent
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

6.  Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.

Authors:  Amal Hofni; Basim A Shehata Messiha; Safwat A Mangoura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-11       Impact factor: 3.000

7.  Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice.

Authors:  Md Zahorul Islam; Cuong Van Dao; Atsushi Miyamoto; Mitsuya Shiraishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-27       Impact factor: 3.000

8.  HuangqiGuizhiWuwu Decoction Prevents Vascular Dysfunction in Diabetes via Inhibition of Endothelial Arginase 1.

Authors:  Hong Cheng; Tian Lu; Jingya Wang; Yucen Xia; Xiaoshu Chai; Minyi Zhang; Yutong Yao; Na Zhou; Sisi Zhou; Xinyi Chen; Weiwei Su; Cunzhi Liu; Wei Yi; Yongjun Chen; Lin Yao
Journal:  Front Physiol       Date:  2020-03-25       Impact factor: 4.566

9.  Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation.

Authors:  Haroldo A Toque; Kenia P Nunes; Lin Yao; James K Liao; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2013-04-08       Impact factor: 3.802

10.  Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1.

Authors:  Anil Bhatta; Lin Yao; Zhimin Xu; Haroldo A Toque; Jijun Chen; Reem T Atawia; Abdelrahman Y Fouda; Zsolt Bagi; Rudolf Lucas; Ruth B Caldwell; Robert W Caldwell
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.